Expert insights report transitioning therapy for CIDP patients from IVIg to subcutaneous efgartigimod, suggesting improved management strategies.
To report expert insight on transitioning patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) from intravenous immunoglobulin (IVIg) to subcutaneous (SC) efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20).
No takes yet. Share an insight, caveat, or question.
Vukic et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: